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Bcl-2 Expression and Clinico-Pathological Correlations in Invasive Ductal
Carcinoma of the Breast
[Ekspresi Bcl-2 dan Korelasi Klinikopatologi dalam Karsinoma Duktus Payudara]
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ABSTRACT
Bcl-2 is an anti-apoptotic protein belonging to a family of proteins that act as regulators of apoptosis in mammalian
cells. Bcl-2 expression has previously been reported in normal breast ductal cells and its involvement in the hormonal
regulation of hyperplasia and involution was further suggested, and it was thought to be expressed through hormone-
dependent pathways. Bcl-2 is a cytoplasmic oncoprotein which is highly expressed in human solid tumours. In breast
cancer cells, however, Bcl-2 expression is down regulated, the exact mechanism and the effects of which are not clearly
defined, as bcl-2 expression appears to be inversely correlated with the presence of p53 mutations. This work aimed at
investigating the expression of bcl-2 in invasive ductal carcinoma of the breast utilizing an immunohistochemistry
assay as well as studying the clinical correlations of bcl-2. Bcl-2 was detected in 43.7% of 382 invasive ductal
carcinoma study cases. Its expression correlated positively, with lower age of patients, higher histological grades,
large tumour sizes, estrogen receptor positivity and progesterone receptor negativity. However, the statistical correlations
were weak. With the data obtained, it was found that the expression of bcl-2 correlated with unfavourable prognoses.
Furthermore, bcl-2 detection alone may not be very helpful in consolidating a clinical diagnosis.
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ABSTRAK
Bcl-2 merupakan protein anti-apoptosis yang termasuk di dalam keluarga protein yang mengatur proses apoptosis sel
mamalia. Bcl-2 telah dilaporkan diekspres di dalam sel duktus payudara normal dan ia juga terlibat di dalam pengaturan
hormon kejadian hiperplasia. Penglibatan Bcl-2 itu dilihat melalui tapakjalan kebergantungan hormon. Selain daripada
itu, Bcl-2 adalah onkoprotein sitoplasma yang mempunyai tahap ekspresi yang tinggi di dalam sel tumor manusia.
Walau bagaimanapun, di dalam sel kanser payu dara, pengawalaturan Bcl-2 menjadi rendah, dan mekanisma sebenar
masih kurang jelas di mana esperesi Bcl-2 berkorelasi secara negatif dengan kehadiran mutasi p53. Kajian ini adalah
bertujuan untuk mengkaji ekspresi Bcl-2 di dalam karsinoma duktus payudara menggunakan kaedah imunohistokimia
dan seterusnya melihat hubungannya dengan aspek klinikal. Hasil kajian mendapati Bcl-2 diekspres sebanyak 43.7%
di dalam 382 kes karsinoma duktus payudara. Ekspresi Bcl-2 berkorelasi positif dengan tahap umur pesakit yang
rendah, gred histologi yang tinggi, tumor saiz besar, reseptor estrogen yang positif dan reseptor progesteron yang
negatif. Walau bagaimanapun, statistik korelasi adalah lemah. Data yang diperolehi telah menunjukkan ekspresi Bcl-
2 berkorelasi dengan prognosis yang tidak baik. Hasil kajian juga mendapati pengesanan hanya ekspresi Bcl-2
sahaja tidak membantu di dalam diagnosis secara klinikal.
Kata kunci: Karsinoma duktus payudara; Bcl-2; korelasi klinikal
INTRODUCTION
B-cell lymphoma-2 protein (Bcl-2) has been the first regulator
of cell death to be discovered (Heiser et al. 2004) and its
family proteins are also important regulators of apoptosis
in mammalian cells (Schinzel et al. 2004). Bcl-2 is an anti-
apoptotic protein (Townsend et al. 2002; Giatromanolaki et
al. 2001) and is also a proto-oncogene (Formby & Wiley
1999; Strasser et al. 1997) that resides on the cytoplasmic
face of the mitochondrial outer membrane, in the
endoplasmic reticulum and in the nuclear envelope
(Schinzel et al. 2004; Mullauer et al. 2001; Robertson et al.
2000). In normal breast, bcl-2 is expressed in the non-
pregnant and non-involuting mammary epithelium and is
expressed through hormone-dependent pathways
(Troncone et al. 1995; Ioachim et al. 2000) such as those of
estrogen and progesterone (Park et al. 2002). Bcl-2 is a
cytoplasmic oncoproteins (Sato et al. 1997; Sierra et al.
1996), which is also highly expressed in human solid
tumours (Arun et al. 2003). In breast cancer cells, however,
bcl-2 expression is down regulated, the exact mechanism
and the effect of which are not clearly defined (Park et al.
2002), although its expression appears to be inversely
correlated with the presence of p53 mutations (El-Ahmady
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et al. 2002; Takei et al. 1995; Van-Slooten et al. 1998). In
reports from many parts of the world, a wide range of bcl-2
expression in breast cancer extending from 25% to over
79% has been documented, some with significant
associations with clinical parameters such as hormone
receptors and prognosis (Giatromanolaki et al. 2001;
Troncone et al. 1995; Ioachim et al. 2000; Sirvent et al. 2004;
Pusztai et al. 2004; Linjawi et al. 2004; Gursan et al. 2001;
Mbonde et al. 2001; Moran et al. 2009; Villar et al. 2001;
Yang et al. 2001; Hamilton et al. 2000; Malamou-Mitsi et al.
2006; Murillo-Oritz et al. 2006; Al-Moundhri et al. 2003).
Furthermore, in breast cancer, it has been suggested that
bcl-2 may have significant correlations with the apoptotic
index, low nuclear grade and absence of mutant p53 (Villar
et al. 2001), small tumour size, non-ductal morphology, and
low tumour grade (Barbareschi et al. 1996), tumour diploid
status (Linjawi et al. 2004), a negative correlation with
increasing histological grade and positive correlation with
rising ER immunostaining (Yang et al. 1999; Martinez-Aribas
et al. 2007). This work was carried out utilizing breast cancer
tissue samples collected from two North-Eastern States in
Malaysia and aimed at investigating the expression and
the clinical correlations of bcl-2 in invasive ductal carcinoma
(IDC) of the breast.
PATIENTS AND METHODS
The subjects of this study were 382 patients with invasive
ductal carcinoma (IDC) of the breast, obtained from three
general hospitals in The North-East Coast of Malaysia:
Hospital of The University of Science of Malaysia (HUSM),
Kota Bharu, Kelantan State, from 1992 to 2004 (n = 266),
Hospital Kota Bharu (HKB), Kota Bharu, Kelantan from
2001 to 2003 (n = 37), and Hospital Kuala Terengganu (HKT),
Kuala Terengganu, Terengganu State, from 2001-2004 (n =
79). The clinical data obtained from the records and the
histopathology reports of the study patients included the
final diagnosis, lymph node metastasis, tumour size, tumour
side, estrogen receptor status (282 cases only) and
progesterone receptor status (259 cases only). The study
was approved by the Ethics Committee Board, Universiti
Sains Malaysia, Kubang Kerian, Kelantan, in September
2001, approval no. 304/PPSP/613336. In addition, consents
from patients for using fresh samples were also taken.
Fresh samples of breast cancer tissue were obtained
from the operations theatre fixed in 10% formalin within 13
hours at room temperature. Older tissue samples in wax
blocks were obtained from the Departments of Pathology
of the three hospitals. For the tissue detection of bcl-2,
tissue sections of the breast mass, 4 µm thick, were
deparaffinized and rehydrated. Following that, all sections
were heated in a microwave oven three times at 900 W for
a total of 15 min in 0.01 M sodium citrate buffer, pH 6.0. A
mouse monoclonal anti human bcl-2 primary antibody
(clone 124; DAKO), diluted 1:50 with phosphate-buffered
saline (PBS), was added and incubated for 1 hour. A
biotinylated rabbit anti-mouse IgG (DAKO), diluted 1:100
with PBS, was added and incubated for 1 hour. The detection
used a standard avidin-biotin-peroxidase complex/ DAB
(ABComplex kit-DAKO). Negative controls were treated with
a pre-immune mouse serum instead of the primary antibody.
The positive control used for bcl-2 was inflamed tonsillar
tissue. All the laboratory work was performed at room
temperature. The scoring criteria for bcl-2 were as those
described previously (Al-Joudi et al. 2007). Briefly, a mean
percentage of bcl-2-positive cells was determined in at least
five areas at × 400 magnification and assigned to one of
the five following categories: (a) 0 < 5% (b) 1 = 5-25% (c) 2
= 26-50% (d) 3 = 51-75% (e) 4 > 75%. The intensity of bcl-2
immunostaining was scored as follows: (a) weak, 1+ or (+);
(b) moderate, 2+ or (++); (c) intense, 3+ or (+++). For tumors
that showed heterogeneous staining, the predominant
pattern was taken into account for scoring. The percentage
of positive cells and the staining intensity were multiplied
to produce a weighted score for each case. Cases with
weighted scores of less than 1 were considered negative.
Cases with scores of > 1 were considered positive. The
cases were scored by two independent observers.
The Pearson Chi-square test (Pearson χ2) and
Spearman rank correlation were measured using The
Statistical Package for Social Sciences (SPSS version 11.0
software package for Macintosh, SPSS Inc., Chicago, IL).
RESULTS
The total positive expression of bcl-2 in invasive ductal
carcinoma of the breast patients was 43.7% (n = 167/382)
(Figure 1-4). Among the positive cases, the expression of
bcl-2 was 30.1% (n = 115) in the patients age group ≤ 50
years compared to 13.6% (n = 52) in age group > 50 years.
With the histological grade parameter, 20.9% (n = 80) of
positive bcl-2 expression were in grade III compared to
16.7% (n = 64) in grade II and 6.0% (n = 23) in histological
grade I. Furthermore, 25.4% (n = 97) of the bcl-2-positive
cases had positive lymph node involvement, whereas 18.3%
(n = 70) had no lymph node involvement. Tumour sizes of
> 10 cm demonstrated the highest positive expression of
bcl-2 (21.7%, n = 83) compared to other tumour sizes. It was
also found that 22.5% (n = 86), of the bcl-2 positive cases
were in the right side breast while 20.1% (n = 77) were in the
left breast and 1.0% (n = 4) were bilateral. Estrogen receptor
negative cases demonstrated higher positive expression
of bcl-2 (28.7%, n = 81) compared to the estrogen receptor
positive (11.7%, n = 33). With the progesterone receptor
parameter, the majority of the positive bcl-2 cases were in
the progesterone receptor negative (30.9%, n = 80)
compared to 9.6% (n = 25) of progesterone receptor positive
cases. However, no significant correlations were
established between the expression of bcl-2 and
clinicopathological factors under investigation, including
the estrogen and progesterone receptor status (p > 0.05)
(Table 1).
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FIGURE 1. A micrograph showing positive cytoplasmic
immunostaining of bcl-2 in IDC of the breast
(magnification ×100)
FIGURE 2. A micrograph showing positive cytoplasmic
immunostaining of bcl-2 in IDC of the breast
(magnification ×400)
FIGURE 3. A micrograph showing the negative control of bcl-2:
inflamed tonsillar tissue with pre-immune primary mouse
serum (magnification ×400)
FIGURE 4. A micrograph showing the positive control of bcl-2:
inflamed tonsillar tissue (magnification ×400)
TABLE 1. The correlation between clinicopathologic factors, hormonal status, and expression of bcl-2 in breast cancer
Bcl-2 expression
Positive (number of patients) Negative (number of patients) Percent-tages p-value
Age (years) (n = 382)
≤ 50 115 143 30.1 n.s.
> 50 52 72 13.6 p = 0.626
Histological grade (n = 382)
I 23 22 6.0% n.s.
II 64 93 16.7% p = 0.450
III 80 100 20.9%
Lymph node metastasis (n = 382)
Node + 97 141 25.4% n.s.
Node - 70 74 18.3% p = 0.134
Tumour size (cm)(n = 382)
< 1 cm 1 0 0.026% n.s.
1-2 cm 4 7 1.0% p = 0.178
2.1 - 5 cm 32 42 8.4%
5.1 – 10 cm 47 81 12.3%
≥ 10 cm 83 85 21.7%
Tumour side (n = 382)
Right 86 98 22.5% n.s.
Left 77 110 20.1% p = 0.493
Bilateral 4 7 1.0%
Estrogen receptor status (n = 282)
Negative 81 106 28.7% n.s.
Positive 33 62 11.7% p = 0.165
Progesterone receptor status (n = 259)
Negative 80 113 30.9% n.s.
Positive 25 41 9.6% p = 0.610
All analyses were tested using Pearson Chi-square test (Pearson χ2) and Spearman rank correlation, p < 0.05 is considered significant, n.s. =
not significant, n = number of patients
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DISCUSSION
Bcl-2 in breast cancer is associated with estrogen receptor
(ER) expression which is a favourable prognostic sign
(Ioachim et al. 2000; Linjawi et al. 2004). Nevertheless, there
are conflicting reports regarding its prognostic value. Many
workers have concluded that bcl-2 expression characterizes
a particular phenotype of breast cancer with a favourable
prognosis, and it may therefore be used as a marker of
long-term survival and modulation of response to adjuvant
therapy (Takei, et al. 1995; Al-Moundhri et al. 2003; Le et al.
1999; Yang et al. 2003), whereas other workers (Martinez-
Arribas et al. 2007; Jansen et al. 1998) found that bcl-2
expression was not a prognostic indicator in breast cancer,
and Dimatrkakis concluded that the detection of bcl-2
expression alone has a limited prognostic value in breast
cancer (Dimitrakakis et al. 2002). Contrary findings have
reported the correlation of bcl-2 expression with tumour
aggression and metastasis (Sierra et al. 1996). In this report,
the data obtained implies that bcl-2 expression correlates
with unfavourable prognosis, since it was detected more
in cases with higher tumour grades and greater tumour
sizes. Such differences in the data may be difficult to
interpret. However, there may be some technical aspects
especially regarding data collection. Furthermore,
differences may vary from on place to another especially
regarding the breast cancer type, and the presentation on
first diagnosis. However, the lack of statistical significance
in the current work does not particularly support this view.
In the current work, the extent of Bcl-2 expression
among IDC patients was found to be 43.7%. Looking at
previous works, this percentage varied up to 79.5%
(Malamou-mitsi et al. 2006; Murrillo-Oritz et al. 2006). The
differences may be attributed to ethnic variations, age
differences, grade and stage expressions, in addition to
technical variations. There are no previous published works
on bcl-2 in breast cancer in The North of Malaysia.
Bcl-2 inhibits apoptosis by blocking the release of
cytochrome c from mitochondria, thereby preventing Apaf-
1 (apoptotic protease-activating factor-1) and consecutive
caspase activation (Eissa et al. 1999). It may also inhibit
apoptosis by binding to the pro-apoptotic molecules Bax
and bcl-x (Mullauer et al. 2001). Bcl-2 protein performs its
oncogenic role by preventing tumour cells from undergoing
apoptosis induced by ã-irradiation, chemotherapeutic
drugs, and hormonal therapy (Heiser et al. 2004; Suzuki et
al. 2004). Hence, it may be responsible for the resistance to
apoptosis induced by chemotherapeutic drugs (Mullauer
et al. 2001; Zhang et al. 1998). In solid tumours, the
expression of bcl-2 is often correlated with good prognosis
(Yang et al. 1999; Le et al. 1999). Nevertheless, down
regulation of bcl-2 expression may reduce cell migration
and metastasis (Sun et al. 2006). This marks the importance
of detecting bcl-2 as a potential target, alone or in
conjunction with other selected cellular targets such as
beclin-1 (Won et al. 2010) or other chemotherapeutic agents
(Moulder et al. 2008) especially with metastatic breast
tumours (Subhawong et al. 2010). In conclusion, the current
work represents the first report on the expression of bcl-2
in breast cancer tissue samples from Malaysia. Although
no strong correlation has been established with most of
the clinical parameters sought, the report remains valuable
for clinicians who choose to predict the response to
adjuvant therapy. Nevertheless, this work sheds some light
on the nature of breast cancer in this region.
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